CN1617755A - 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 - Google Patents

法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 Download PDF

Info

Publication number
CN1617755A
CN1617755A CNA028239202A CN02823920A CN1617755A CN 1617755 A CN1617755 A CN 1617755A CN A028239202 A CNA028239202 A CN A028239202A CN 02823920 A CN02823920 A CN 02823920A CN 1617755 A CN1617755 A CN 1617755A
Authority
CN
China
Prior art keywords
amount
day
administered
fpt inhibitor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028239202A
Other languages
English (en)
Chinese (zh)
Inventor
D·L·库特勒尔
M·L·迈尔斯
C·鲍姆
S·L·扎克诺恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1617755A publication Critical patent/CN1617755A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA028239202A 2001-11-30 2002-11-25 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 Pending CN1617755A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33441101P 2001-11-30 2001-11-30
US60/334,411 2001-11-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2007101860344A Division CN101181269A (zh) 2001-11-30 2002-11-25 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用

Publications (1)

Publication Number Publication Date
CN1617755A true CN1617755A (zh) 2005-05-18

Family

ID=23307076

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA028239202A Pending CN1617755A (zh) 2001-11-30 2002-11-25 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用
CNA2007101860344A Pending CN101181269A (zh) 2001-11-30 2002-11-25 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007101860344A Pending CN101181269A (zh) 2001-11-30 2002-11-25 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用

Country Status (13)

Country Link
US (2) US20030185831A1 (enExample)
EP (1) EP1448268A2 (enExample)
JP (1) JP2005511663A (enExample)
CN (2) CN1617755A (enExample)
AU (1) AU2002352941A1 (enExample)
BR (1) BR0214564A (enExample)
CA (1) CA2468839A1 (enExample)
HU (1) HUP0402401A2 (enExample)
MX (1) MXPA04005207A (enExample)
NO (1) NO20042730L (enExample)
NZ (1) NZ532562A (enExample)
WO (1) WO2003047697A2 (enExample)
ZA (1) ZA200403737B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2498982A1 (en) * 2002-07-24 2004-01-29 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
AU2004289256A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl tranferase inhibitor with an antihormonal agent for the treatment of breast cancer
AU2005216898A1 (en) * 2004-02-26 2005-09-09 The Penn State Research Foundation Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
WO2007042465A2 (en) * 2005-10-07 2007-04-19 Novartis Ag Combinati0n of nilotinib with farnesyl transferase inhibitors
JP2010507662A (ja) * 2006-10-25 2010-03-11 シェーリング コーポレイション 癌の処置のための不連続方法
EP2088862A4 (en) * 2006-11-28 2009-12-02 Smithkline Beecham Cork Ltd METHOD OF TREATING CANCER
EP4615842A1 (en) 2022-11-09 2025-09-17 Merck Patent GmbH Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
CZ298511B6 (cs) * 1997-12-22 2007-10-24 Schering Corporation Použití benzocykloheptapyridinových sloucenin proprípravu farmaceutického prípravku pro použití v kombinaci s antineoplastickým lécivem a/nebo radioterapií k lécení proliferacních onemocnení
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
JP5491681B2 (ja) * 2000-02-04 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
EP1267848B1 (en) * 2000-02-24 2007-10-17 Janssen Pharmaceutica N.V. Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
WO2001064252A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
WO2001064199A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
BR0114430A (pt) * 2000-10-05 2004-01-06 George Q Daley Processos para a indução da morte de células cancerìgenas e para a regressão de tumor

Also Published As

Publication number Publication date
CN101181269A (zh) 2008-05-21
NO20042730L (no) 2004-06-29
WO2003047697A3 (en) 2003-10-30
ZA200403737B (en) 2005-05-23
BR0214564A (pt) 2004-11-09
MXPA04005207A (es) 2004-08-19
US20030185831A1 (en) 2003-10-02
HUP0402401A2 (hu) 2005-03-29
EP1448268A2 (en) 2004-08-25
JP2005511663A (ja) 2005-04-28
NZ532562A (en) 2007-02-23
CA2468839A1 (en) 2003-06-12
AU2002352941A1 (en) 2003-06-17
WO2003047697A2 (en) 2003-06-12
US20060183765A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
CN1419452A (zh) 协同治疗癌症的方法和组合物
CN1496256A (zh) 用于治疗增生性疾病的埃博霉素(epo thilone)类似物和化疗剂的组合
CN1735415A (zh) 使用免疫调节化合物治疗和控制癌症和其他疾病的方法和组合物
CN1711094A (zh) Src家族非受体酪氨酸激酶抑制剂和吉西他滨的组合产品
CN1366881A (zh) 用雌激素激动剂/拮抗剂治疗某些癌症的方法
CN1364084A (zh) 诱导癌细胞死亡和肿瘤消退的方法
CN1774265A (zh) 神经再生药
CN101039673A (zh) 用于治疗涉及细胞增殖的疾病的组合
CN1655784A (zh) 有效的选择性阿片受体调制剂化合物的用途
CN1835948A (zh) 2－酰基氨基噻唑衍生物或其盐
CN1610549A (zh) 用于治疗难治肿瘤的埃坡霉素衍生物
CN1735412A (zh) 利用选择性细胞因子抑制药物治疗和控制癌症和其它疾病的方法和组合物
CN1617755A (zh) 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用
CN1129431C (zh) 苯并芳庚并吡啶类化合物与抗肿瘤药联合用于治疗增生性疾病
CN1668299A (zh) 使用jnk抑制剂治疗或预防与疾病－相关的消瘦的方法
CN1784232A (zh) 包含抗血管生成剂和Src抑制剂的联合的治疗药物及其治疗用途
CN1849119A (zh) 用于增生性疾病的治疗的src激酶抑制剂和化学治疗剂的组合
CN1805749A (zh) 星孢素衍生物的新药物用途
CN1139383C (zh) 用于借助细胞毒试剂治疗肿瘤过程的含异黄酮类的治疗组合物
CN1832747A (zh) 包含星孢素的组合
CN1139384C (zh) 用于与细胞毒性剂治疗肿瘤的基于类黄酮的治疗组合物
CN1509763A (zh) 人肿瘤坏死因子-α突变体的应用
CN1220490C (zh) 哌嗪环氧乙烷衍生物在制备用于诱导肿瘤细胞死亡的药物中的应用
CN100338066C (zh) 六环化合物
CN1942189A (zh) 5,10－亚甲基四氢叶酸在癌症治疗中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication